EU regulator declines to back Mirati's lung cancer drug (updated)

Mirati Therapeutics

21/07/2023 11:38

(Adds details in paragraph 2 and background in paragraphs 3 and
4)
       July 21 (Reuters) - The European Medicines Agency's
panel declined to back authorization for Mirati Therapeutics'
 MRTX.O  drug to treat a type of lung cancer as it did not
fulfill the requirements for conditional support.
    Mirati said on Friday it disagrees with the EMA's opinion
and intends to request a formal re-examination, but gave no
details on the requirements it did not fulfill.
    Its drug, adagrasib, approved by the U.S. Food and Drug
Administration in December, is designed to target a mutated form
of a gene known as KRAS that occurs in about 13% of non-small
cell lung cancers, the most common form of the disease, and less
frequently in some other solid tumors.
    

 (Reporting by Leroy Leo in Bengaluru; Editing by Shinjini
Ganguli)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))